DekaBank Deutsche Girozentrale’s Amicus Therapeutics FOLD Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-217,700	Closed	-$2.81M	–	1193
2025 Q4	$2.81M	Hold	217,700	–	–	﹤0.01%	695
2025 Q3	$1.73M	Hold	217,700	–	–	﹤0.01%	778
2025 Q2	$1.28M	Hold	217,700	–	–	﹤0.01%	814
2025 Q1	$1.8M	Hold	217,700	–	–	﹤0.01%	748
2024 Q4	$2.07M	Hold	217,700	–	–	﹤0.01%	741
2024 Q3	$2.3M	Hold	217,700	–	–	﹤0.01%	727
2024 Q2	$2.13M	Hold	217,700	–	–	﹤0.01%	746
2024 Q1	$2.56M	Hold	217,700	–	–	﹤0.01%	709
2023 Q4	$3.17M	Hold	217,700	–	–	0.01%	679
2023 Q3	$2.58M	Hold	217,700	–	–	0.01%	688
2023 Q2	$2.73M	Hold	217,700	–	–	0.01%	684
2023 Q1	$2.33M	Hold	217,700	–	–	0.01%	697
2022 Q4	$2.59M	Hold	217,700	–	–	0.01%	668
2022 Q3	$2.19M	Hold	217,700	–	–	0.01%	689
2022 Q2	$2.3M	Buy	217,700 +120,000	+123%	+$988K	0.01%	690
2022 Q1	$939K	Buy	97,700 +8,900	+10%	+$83.5K	﹤0.01%	919
2021 Q4	$1.06M	Buy	88,800 +2,500	+3%	+$27.9K	﹤0.01%	925
2021 Q3	$855K	Hold	86,300	–	–	﹤0.01%	936
2021 Q2	$855K	Hold	86,300	–	–	﹤0.01%	952
2021 Q1	$806K	Hold	86,300	–	–	﹤0.01%	947
2020 Q4	$1.94M	Sell	86,300 -74,300	-46%	-$1.52M	0.01%	675
2020 Q3	$2.22M	Buy	+160,600	New	+$2.34M	0.01%	576
2019 Q4	–	Sell	-118,600	Closed	-$957K	–	1169
2019 Q3	$957K	Sell	118,600 -126,000	-52%	-$1.37M	0.01%	677
2019 Q2	$2.94M	Buy	244,600 +177,800	+266%	+$2.26M	0.01%	542
2019 Q1	$909K	Sell	66,800 -20,500	-23%	-$250K	0.01%	790
2018 Q4	$810K	Buy	87,300 +20,500	+31%	+$225K	0.01%	736
2018 Q3	$909K	Sell	66,800 -1,700	-2%	-$23.8K	0.01%	807
2018 Q2	$1.06M	Sell	68,500 -1,000	-1%	-$15.1K	0.01%	733
2018 Q1	$1.01M	Sell	69,500 -1,400	-2%	-$21.3K	0.01%	720
2017 Q4	$893K	Hold	70,900	–	–	0.01%	711
2017 Q3	$893K	Hold	70,900	–	–	0.01%	719
2017 Q2	$704K	Hold	70,900	–	–	0.01%	767
2017 Q1	$511K	Sell	70,900 -6,000	-8%	-$37.9K	﹤0.01%	736
2016 Q4	$370K	Buy	76,900 +6,000	+8%	+$41.5K	﹤0.01%	714
2016 Q3	$501K	Hold	70,900	–	–	0.01%	663
2016 Q2	$384K	Buy	70,900 +17,000	+32%	+$119K	﹤0.01%	725
2016 Q1	$431K	Sell	53,900 -6,500	-11%	-$46K	0.01%	686
2015 Q4	$582K	Buy	60,400 +1,000	+2%	+$9.01K	0.01%	666
2015 Q3	$831K	Buy	59,400 +12,900	+28%	+$202K	0.01%	578
2015 Q2	$658K	Buy	46,500 +1,700	+4%	+$20.4K	0.01%	644
2015 Q1	$487K	Buy	+44,800	New	+$395K	0.01%	721
2014 Q1	–	Sell	-28,500	Closed	-$66K	–	973
2013 Q4	$66K	Buy	28,500 +1,000	+4%	+$2.19K	﹤0.01%	782
2013 Q3	$64K	Buy	27,500 +1,500	+6%	+$3.76K	﹤0.01%	771
2013 Q2	$60K	Buy	+26,000	New	+$79.9K	﹤0.01%	700

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

DekaBank Deutsche Girozentrale's FOLD Position: Q1 2026 in Review

DekaBank Deutsche Girozentrale sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 217,700 shares — an estimated $2.81M sold.

DekaBank Deutsche Girozentrale first reported a position in FOLD in Q2 2013 and held it in 44 quarters. The position peaked at $3.17M in Q4 2023. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

DekaBank Deutsche Girozentrale reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 217,700 Amicus Therapeutics shares in Q1 2026, an estimated $2.81M.
DekaBank Deutsche Girozentrale first reported a position in Amicus Therapeutics in Q2 2013 and held it in 44 quarters.
DekaBank Deutsche Girozentrale's Amicus Therapeutics position peaked at $3.17M in Q4 2023.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2026, filed 7 May 2026.